secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0000950170-24-129488
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio receives Australian clearance to begin Phase 1/2a study of KRRO-110 for Alpha-1 Antitrypsin Deficiency
--------------------------------------------------------------------------------

- Australian HREC approval and TGA clearance obtained for Phase 1/2a REWRITE study of KRRO-110 in AATD.
- First participant dosing expected Q1 2025; interim readout H2 2025; study completion anticipated 2026.
- KRRO-110 aims to edit RNA to produce functional M-AAT; in mouse model, >60% editing achieved at therapeutically relevant levels.
- Study will evaluate safety, tolerability, PK/PD of single and multiple ascending doses in PiZZ genotype patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024129488/0000950170-24-129488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024129488/krro-20241121.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-129488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer